SBBP Strongbridge Biopharma plc

4.5
-0.01  -0%
Previous Close 4.51
Open 4.55
Price To Book 2.15
Market Cap 243755766
Shares 54,167,948
Volume 20,439
Short Ratio
Av. Daily Volume 168,071

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data expected 4Q 2019.
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 data met primary endpoint August 8, 2018. New data presented at ENDO March 23, 2019.
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome

Latest News

  1. Does Strongbridge Biopharma plc's (NASDAQ:SBBP) CEO Pay Compare Well With Peers?
  2. Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress
  3. Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
  4. Is Strongbridge Biopharma plc (NASDAQ:SBBP) Potentially Underrated?
  5. Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
  6. Strongbridge Biopharma plc Announces New Employment Inducement Awards
  7. Edited Transcript of SBBP earnings conference call or presentation 26-Feb-19 1:30pm GMT
  8. What's in the Cards for Aeterna (AEZS) This Earnings Season?
  9. Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO)
  10. Strongbridge Biopharma plc to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference
  11. Strongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference Call Transcript
  12. Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2018 Financial Results
  13. Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
  14. Strongbridge Biopharma plc to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call on February 26, 2019
  15. What Kind Of Investor Owns Most Of Strongbridge Biopharma plc (NASDAQ:SBBP)?
  16. These 2 Biotech Stocks Seem Significantly Undervalued
  17. Strongbridge completes $181.7M sale of hormone drug to Novo Nordisk
  18. Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada
  19. Do Hedge Funds Love Strongbridge Biopharma plc (SBBP)?
  20. Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes — New Research Emphasizes Economic Growth